Pharvaris N.V. is a biopharmaceutical company focused on developing breakthrough therapies for hereditary angioedema (HAE) and other rare diseases. Leveraging its expertise in small molecule design and V2 receptor antagonism, Pharvaris is committed to improving the lives of patients through innovative treatments.
